Loading...
Please wait, while we are loading the content...
Similar Documents
Oral vinorelbine: feasibility and safety profile.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Depierre, Alain Freyer, Gilles Jassem, Jacek Orfeuvre, Hubert Ramlau, Rodryg Adam Lemarié, Etienne Koralewski, Piotr M. Mauriac, Louis Breton, Jean Luc Delozier, Thierry Trillet-Lenoir, Véronique |
| Copyright Year | 2001 |
| Abstract | BACKGROUND Patient preference as well as concerns and difficulties with intravenous access and pharmaco-economic issues have driven the development of oral vinorelbine. PATIENTS AND METHODS Four phase II studies were conducted in chemotherapy-naive non-small-cell lung cancer (NSCLC) and as first-line chemotherapy of advanced breast cancer (ABC). As recommended in the phase I dose-finding study, the first step used a weekly dose of 80 mg/m2. This regimen was associated with an excessive rate of early deaths (10%) due to complicated neutropenia and led to discontinuation of the first two studies. In a second step, the dose of 60 mg/m2/week was given for the first three courses and subsequently increased to 80 mg/m2/week, in the absence of severe neutropenia. RESULTS One hundred and thirty eight patients (76 with NSCLC and 62 with ABC) received this regimen, of whom only five were unable to undergo dose escalation. The incidence of febrile neutropenia and neutropenic sepsis were low (2.9 and 3.6%, respectively). Although severe events were uncommon, nausea/vomiting and diarrhoea were frequent and primary prophylaxis with antiemetics should be recommended. CONCLUSIONS Overall, the safety profile of oral vinorelbine at 60 mg/m2/week for the first three courses with escalation to 80 mg/m2 is qualitatively comparable to that of i.v. vinorelbine at standard doses. Similarly to i.v. chemotherapy, close haematological monitoring is necessary. |
| Starting Page | 578 |
| Ending Page | 581 |
| Page Count | 4 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/12/12/10.1023_A_1013567022670/3/12-12-1677.pdf?Expires=1492531431&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=C0he3ZroonX2-geJs90Wv06GpOmJWnABHGzxq5RNL~MQUWeGZZFFx4RAqKKhlAoc6lLvwt6NJ0bCyMIK1r2nzhlR6mPVn9hoVo-mFKcBUyHnffXrMTOxppN41r4VOucBkWl~nrMCjawIwHXiEQvF0J9kbtzKw9DVwUkcmjeN6Tt0FLytoxSA4haLBH6~hs-~cjFP5Zvq66vlLnJVPwuXfs~tSpleX9QNSq~Ax6IXgjPo1vztEcOHYPuRkZS2SGw0iMncHQUuPDn7RBUFHzUfRHeBad9Z-7s0bpi9dS1NWgq1anAP4EOmbJFi62xLdkw-b4A-BFbmhZwEwX2cD38rNA__ |
| Alternate Webpage(s) | https://watermark.silverchair.com/12-12-1677.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAbIwggGuBgkqhkiG9w0BBwagggGfMIIBmwIBADCCAZQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMAJc04Mi2rsdBNvASAgEQgIIBZZe-badeZ7974fApAeZo1PtOIKUfDdd_7WVGjpYflAYLl3rIq_gYNJ7GVKalqBwjtzfCy_wcJGdCVjcGLyjXiSAwg5vAsBVxq_VhfoUUvjbieHKU2tQvyONjk6w6uJzQj3KY5_PgGlo3xBMKBmdfjRIgUlzBoZwgVloTDz0PHsI2ca_pXTtzzjVGJD1-y-ViNukynb0DT6pDwrn63MPozTYPnuzmySeT3OqfxU63qjMToOlPfhSej-1-ofz82iTi4p_v2SkpGJzFKR9TVcfPXo0QOnoC73YQPIUFM2xutWyHsbvbk4wyqeCcAL-t9bmjdnQYZss7XcNFBAKmx-1t-inGa5A6XWzJ5ActLXvQhlbuNciJwl_3bw469gKqp7I3e4L2Ph_BUb1IuAFlfRs3LeTvlwXM9y9H1zz7wkfUncA4uTVB6tp7sdcc5obju3qpnEucfPJza8-Eqbaa5EhNUqDjRykniA |
| PubMed reference number | 11843244v1 |
| Volume Number | 12 |
| Issue Number | 12 |
| Journal | Annals of oncology : official journal of the European Society for Medical Oncology |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Antiemetics Carcinoma of lung Cessation of life Diarrhea Eighty Escalation Febrile Neutropenia Fever Mammary Neoplasms Milligram per Square Meter per Week Nausea and vomiting Non-Small Cell Lung Carcinoma Patients Sepsis vinorelbine |
| Content Type | Text |
| Resource Type | Article |
